- Full text PDF available (2)
- This year (0)
- Last 5 years (4)
- Last 10 years (7)
Journals and Conferences
1The Advanced Centre for Biochemical Engineering, University College London, London, UK 2The Harvard Stem Cell Institute, Cambridge, MA, USA 3Harvard Business School, Boston, MA, USA 4London Regenerative Medicine Network, London, UK 5Harvard Medical School, Center for Excellence in Vascular Biology, Boston, MA, USA 6Future Medicine Ltd, London, UK 7Lonza… (More)
The cell therapy industry (CTI) is presently a small but potentially rapidly growing new global healthcare sector. Success is totally dependent on resolving a number of factors unique to cells as therapies, including: manufacturing, enabling technologies, regulation, reimbursement and essential infrastructure. To understand how to solve these challenges in… (More)
Stock market volatility in the cell therapy industry has greatly hindered the investment necessary to fund translational therapies. Here, we review the volatility of leading companies and suggest that a distinct industry is maturing to a point at which the volatility should subside, providing a more attractive environment for future growth.
The aim of this perspective piece is to highlight how the "social perception" and "financial reality" of regenerative medicine may act to hinder its evolution into the principal health-care option for the future. We also consider the role of the consumer and the need for increased public awareness. Furthermore, we consider the effects of the changing social… (More)
T he cell therapy industry (CTI) is no longer a cottage industry; it is a distinct and sustainable component of the global healthcare sector (1). Today, CTI prospects are strong, with annual revenues exceeding US$1 billion/year, supported by improving investor sentiment and public support (1–3). The next phase of CTI growth — toward a multibillion-dollar… (More)
In the first quarter of 2012, publicly traded companies in the cell-based therapy industry continued to show promising overall growth. Highlights included $85 million in new capital investment and steady clinical trial progress.